caplacizumab-yhdp

Drug Overview:

Caplacizumab-yhdp, marketed under the brand Cablivi, serves as a pioneering von Willebrand factor (vWF)-directed therapy for adults with acquired thrombotic thrombocytopenic purpura (aTTP). This nanobody-based agent represents a breakthrough in managing this rare, life-threatening hematologic emergency characterized by microvascular thrombosis due to ADAMTS13 deficiency. Administered via injection, it rapidly inhibits platelet aggregation, complementing plasma exchange (PEX) and immunosuppression for improved outcomes in international patient populations.

Generic name: Caplacizumab-yhdp
US Brand names: Cablivi
Drug Class: Von Willebrand factor-directed antibody fragment (nanobody-based targeted therapy)
Route of Administration: Intravenous (initial bolus) and subcutaneous injection
FDA Approval Status: Approved February 6, 2019, for aTTP in combination with plasma exchange and immunosuppressive therapy (post-approval data through 2025 confirms sustained utility)

What Is It and How Does It Work? (Mechanism of Action)

Caplacizumab-yhdp functions as a highly specific targeted therapy, leveraging single-domain antibody technology to inhibit vWF-platelet interactions at the molecular level. In aTTP, uncleaved ultra-large vWF multimers adhere to platelets under high shear stress, forming microthrombi; caplacizumab prevents this by locking vWF in an inactive state, addressing the core pathophysiology without broadly impairing hemostasis.

Binds with high affinity (picomolar range) to the A1 domain of vWF, sterically inhibiting interaction with platelet glycoprotein Ib-IX-V (GPIb-IX-V) receptor without direct competition for the binding site, as revealed by high-resolution crystallography
Stabilizes vWF in a compact, low-activity conformation under high shear stress conditions in microvasculature, preventing spontaneous unfolding and exposure of the GPIb-binding site that triggers platelet tethering and aggregation
Reduces formation and persistence of vWF-platelet strings on activated endothelial surfaces, limiting microvascular thrombus propagation while sparing primary hemostasis in larger vessels via collagen-dependent mechanisms
Exhibits no impact on other coagulation factors, fibrin formation, or thrombin generation pathways, ensuring selective modulation of vWF-dependent pathology in aTTP

FDA-Approved Clinical Indications

Caplacizumab-yhdp is approved exclusively for non-oncological use in acute hematologic emergencies, highlighting its niche role in precision medicine for rare disorders. Routine ADAMTS13 testing identifies eligible patients, with no evidence supporting oncological applications despite microvascular involvement in some cancers.

Non-oncological uses: Treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange (PEX) and immunosuppressive therapy (e.g., corticosteroids, rituximab) to reduce platelet aggregation and thrombus formation
Oncological uses: None approved or studied; not indicated for cancer-associated thrombotic microangiopathies

Dosage and Administration Protocols

Dosing for caplacizumab-yhdp is protocol-driven, synchronized with PEX to achieve rapid therapeutic levels followed by maintenance subcutaneous therapy. This regimen minimizes hospital stays, with no dose modifications required for renal or mild-moderate hepatic impairment, facilitating use in diverse patient profiles.

Patient Population	Standard Dose	Frequency	Infusion/Injection Times	Dose Adjustments
Adults with aTTP (Loading, Day 1 prior to first PEX)	11 mg	Single IV bolus	Over at least 15 minutes	None
Adults with aTTP (Daily during PEX therapy)	11 mg	SC once daily, after each PEX session	N/A (SC)	None for renal/hepatic
Post-PEX completion	11 mg	SC once daily	N/A	Continue minimum 30 days; extend if aTTP evidence persists (ADAMTS13 <10%) up to 56 days total
Renal Impairment (any CrCl)	No change	Same	Same	Safe; no adjustment
Hepatic Impairment (mild-moderate Child-Pugh A/B)	No change	Same	Same	Monitor; severe (C) not studied

Clinical Efficacy and Research Results

Landmark phase 3 HERCULES (NCT02553317, results 2017-2021 publications) and phase 2 TITAN (NCT01148844, long-term follow-up to 2025) trials provide robust evidence for caplacizumab-yhdp in aTTP. These studies enrolled ~150 patients, showing faster normalization of platelet counts and fewer disease recurrences versus placebo plus standard care.

Primary endpoint in HERCULES: Median time to confirmed platelet count response (platelet ≥50 × 10⁹/L, LDH normalization, no PEX in prior 24h) reduced by 39% (exact medians: caplacizumab shorter vs placebo; HR favoring treatment)
Exacerbations (post-response TTP recurrence): 67% relative risk reduction (3/75 caplacizumab vs 12/73 placebo; 4% vs 16%)
TITAN/HERCULES pooled: Median durable response time 4.5 days (fast responders) vs 10.5 days placebo; 12-month relapse-free survival improved in the caplacizumab arm
Real-world 2020-2025 data: Shorter PEX duration (mean 5-7 days), reduced ICU needs, supporting cost-effectiveness in European/US settings

Safety Profile and Side Effects

Black Box Warning: Caplacizumab-yhdp increases bleeding risk, including severe, life-threatening, or fatal events (e.g., intracranial hemorrhage). Epistaxis and gingival bleeding predominate; monitor closely, withhold for major bleeds, and avoid antihemostatics.

Caplacizumab-yhdp’s profile reflects its anti-adhesive mechanism, with bleeding as the principal concern balanced against aTTP mortality risk (up to 20% untreated).

Common Side Effects (>10%)

Epistaxis (nosebleeds, 45%; manage with nasal compression 10-15 min, cauterize if recurrent; ENT referral if >30 min)
Gingival bleeding (27%; soft toothbrush, avoid flossing/aspirin; rinse with tranexamic acid if needed)
Headache (25%; hydration, acetaminophen; urgent imaging if thunderclap/severe to exclude ICH)
Fatigue/abdominal pain (13-15%; supportive care, monitor hemoglobin for occult bleed)

Serious Adverse Events

Major bleeding (GI, retroperitoneal, 5-10%; hemodynamic stabilization, endoscopy/transfusion; permanent discontinuation)
Post-treatment TTP recurrences (due to autoantibody persistence; monitor ADAMTS13 q2-4 weeks; restart PEX/immunosuppression)
Hypersensitivity/injection reactions (rare anaphylaxis; epinephrine ready, premedicate if history)

Patient Management and Practical Recommendations

Optimal caplacizumab-yhdp use demands hematologist-led protocols with vigilant bleeding surveillance and ADAMTS13 monitoring to prevent relapses. Patient education enhances adherence in home settings post-hospitalization.

Pre-treatment Tests

ADAMTS13 activity (<10% confirms aTTP), schistocyte smear, LDH, haptoglobin, platelet count, creatinine
Coagulation (PT/PTT, fibrinogen), anti-ADAMTS13 antibodies, pregnancy test (Category C)
Head CT if neurologic symptoms; bleeding risk assessment (e.g., recent surgery)

Precautions During Treatment

Daily platelet/LDH checks; weekly ADAMTS13 during/after therapy
Prophylaxis against bleeding: Avoid NSAIDs/IM injections; hypertension control
Home injection training; 24/7 access to PEX center

Do’s and Don’ts

Do inject SC in abdomen/thigh post-PEX; rotate sites
Do seek immediate care for severe headache, melena, hematuria
Don’t take aspirin/antiplatelets; double-check drug interactions
Don’t stop abruptly without hematology consult

Legal Disclaimer

This guide offers general educational information on caplacizumab-yhdp and does not replace professional medical advice, diagnosis, or treatment. Individualized decisions require consultation with qualified healthcare providers, considering full clinical context, guidelines, and potential risks/benefits.